Lisa Connery
YOU?
Author Swipe
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the <span>SURMOUNT</span> ‐1 to ‐4 trials Open
Aims This analysis evaluated whether gastrointestinal (GI) adverse events (AEs) including nausea, vomiting, diarrhoea (N/V/D) and dyspepsia were associated with weight reduction with tirzepatide across the SURMOUNT‐1 to ‐4 trials. Material…
View article: Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity Open
Importance The effect of continued treatment with tirzepatide on maintaining initial weight reduction is unknown. Objective To assess the effect of tirzepatide, with diet and physical activity, on the maintenance of weight reduction. Desig…
Tirzepatide Once Weekly for the Treatment of Obesity Open
In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
View article: Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia
Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia Open
ClinicalTrials.gov Identifiers: NCT03398005 and NCT03361501.
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes Open
OBJECTIVE This trial compared the efficacy and safety of the first oral glucagon-like peptide 1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with type 2 diabetes managed by diet and exercise alone. Tw…